🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07762443
Starting soon Phase 1

A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata

NCT07762443 · tracked via the Priya Life Science China tracker
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Phase
Phase 1
Started
2026-09-30
Last updated
2026-08-13

Condition(s) studied

Alopecia Areata

Investigational drug(s) / intervention(s)

VC005 tablets

VC005 tablets: VC005 repeat administration for 24 weeks

Study summary

This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia areata (AA).

Eligibility

Sex
ALL
Min age
12 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * The subject fully understands this study and is able to comply with the relevant trial procedures. The subject and their legal guardian voluntarily sign the informed consent form (ICF). * Age 12 to 18 years inclusive (including 12 years old, excluding 18 years old) at the time of signing the ICF, both genders, with body weight ≥ 40 kg. * Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits. Exclusion Criteria: * Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period. * Subjects with a current diagnosis of acute diffuse alopecia areata (AA). * Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc. * Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Peking University People's Hospital Beijing Beijing Municipality

More Jiangsu vcare pharmaceutical technology co., LTD trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07762443 on ClinicalTrials.gov ↗ ← All trials in China